Nexalin Technology Partners with Carmi Masha in Israel's Market
Nexalin Technology, Inc. (NASDAQ: NXL) is taking significant strides in expanding its influence in the neurostimulation field. With an exclusive distribution agreement, Nexalin has teamed up with Carmi Masha Technologies Ltd., a reputable distributor in the medical device arena based in Israel. This collaboration aims to effectively market and sell Nexalin’s second-generation neurostimulation device, the SYNC Console, which operates at 15 milliamp (mA).
Distribution Agreement Highlights
The recent agreement marks a pivotal moment for Nexalin as it receives the green light from the Israeli Ministry of Health for the commercial sale of the SYNC device. This advanced technology is designed to address a variety of mental health disorders like insomnia, depression, and anxiety. Notably, both Nexalin and Carmi Masha are also setting their sights on future applications of this cutting-edge technology to treat post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and Alzheimer’s disease, enhancing the range of therapeutic options available on a global scale.
Collaboration Objectives
Under the terms of their partnership, Carmi Masha will spearhead all facets of sales, marketing, and clinical education within Israel. This entails managing the importation, registration, and distribution of the SYNC device across various healthcare facilities, including hospitals, clinics, and private treatment centers.
Leadership Insights
Mark White, the CEO of Nexalin Technology, expressed enthusiasm about the partnership with Carmi Masha Technologies, emphasizing that their expertise will greatly assist in penetrating the Israeli market. He stated, “With regulatory approval now secured, this exclusive agreement enables us to rapidly initiate commercial activities. Our non-invasive, drug-free technology promises a brighter future for patients seeking alternatives to traditional mental health treatments.”
Commitment to Mental Health
Mark’s sentiment is echoed by Mr. Alex Harel, CEO of Carmi Masha Technologies Ltd., who underlined the crucial nature of this collaboration. He noted, “We are excited to collaborate with Nexalin to introduce this innovative neurostimulation platform to Israel, meeting the growing demand for effective, drug-free treatments for mental health disorders.”
About Nexalin Technology
Nexalin Technology is pro-actively engaged in the battle against the ongoing global mental health epidemic through its innovative product designs which focus on neurostimulation. Each product is developed to be non-invasive and is designed to provide notable relief for those dealing with mental health challenges. The technology utilized in their devices employs bioelectronic frequency-based methodologies capable of penetrating deep into the mid-brain, aiming to alleviate symptoms associated with mental health disorders. Studies suggest that these advanced devices optimize patient responses while minimizing potential adverse side effects.
Global Reach
Notably, Nexalin's Gen-2 neurostimulation device has gained approvals in various countries including China, Brazil, Oman, and Israel. This reinforces the company’s commitment to providing effective treatments across diverse international markets.
Contact Information
For more information about Nexalin and its innovative offerings, interested parties can reach out to Crescendo Communications, LLC at (212) 671-1020 or via email at NXL@crescendo-ir.com.
Frequently Asked Questions
What does Nexalin Technology specialize in?
Nexalin Technology focuses on developing innovative neurostimulation products aimed at alleviating mental health disorders without the use of invasive procedures or pharmaceuticals.
Who is partnering with Nexalin for distribution in Israel?
Nexalin has engaged Carmi Masha Technologies Ltd. as its exclusive distributor in Israel, responsible for marketing and selling the SYNC device.
What is the SYNC device used for?
The SYNC device is designed to treat various mental health issues, including insomnia, depression, and anxiety, and is approved for commercial sale in Israel.
How is the SYNC device different from traditional treatments?
This device is non-invasive and offers a drug-free solution for mental health treatment, setting it apart from conventional therapies that often require medications or surgeries.
Where else has Nexalin’s technology been approved?
In addition to Israel, Nexalin’s devices have received regulatory approvals in countries including China, Brazil, and Oman, highlighting their growing international presence.
